Innoviva, Inc.
A biopharmaceutical royalty company that developed respiratory medicines in partnership with GlaxoSmithKline, including the Ellipta inhaler products Breo and Anoro, and now earns ongoing royalties from those drugs. It was born in 2014 when the drug developer Theravance split in two: the research-and-development arm became Theravance Biopharma, while the royalty business took the name Innoviva. The name blends "innovation" and "vival"—a nod to the company's core role of keeping proven medicines alive in the market.
Granted 127.8K
Granted 9.8K
Granted 9.8K
Granted 9.8K
Granted 39.1K
Granted 12.8K
Granted 9.8K
Granted 15.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Raifeld PavelChief Executive Officer, Director · 4 transactions | +78.8% | 284.8K | 127.8K | — | — |
| Haimovitz JulesDirector · 1 transaction | +6.8% | 152.7K | 9.8K | — | — |
| DiPaolo MarkDirector · 1 transaction | +7.5% | 140.5K | 9.8K | — | — |
| Schlesinger Sarah J.Director · 1 transaction | +7.5% | 140.5K | 9.8K | — | — |
| Basso StephenChief Financial Officer · 4 transactions | +76% | 88.0K | 39.1K | — | — |
| Zhen MarianneChief Accounting Officer · 3 transactions | +22.9% | 56.4K | 12.8K | — | — |
| Small Derek ADirector · 1 transaction | +27.8% | 45.0K | 9.8K | — | — |
| Linden JosephineDirector · 2 transactions | — | 0 | 15.2K | — | — |
Select a row to see that insider’s individual transactions.